TICKERNERD
Menu
TARSTARSHealthcare · Biotechnology

TARS Stock Forecast: Tarsus Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$80
+0.81% on the day

The 8 Wall Street analysts covering Tarsus Pharmaceuticals, Inc. hold a median 12-month price target of $100 — +24.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 14 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$3.7B
Ticker Nerd rank
83 / 100
Median analyst target
$100
Analysts covering
8
Revenue$173.9M+69.4% y/y
Operating income−$19.9M
Net income−$18.6M
Free cash flow$57.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−11.9%
1M
+15.5%
YTD
−2.4%
1Y
+62.0%
From 52W high
−11.9%
From 52W low
+61.2%
$50
$91
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TARS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tarsus Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026
83 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
98
Quality
97
Volatility
94
Accruals
83
Momentum
72
Growth
69
Revisions
42
Size
28
Issuance
23

Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (23): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TARS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TARS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$60$70$80$90$100$110Oct 25Jan 26Apr 26Jul 26TARSHigh $105Median $100Low $84

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $84Median $100High $105

The green dot is the last close — the median target sits +24.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
8 Sept 2026JefferiesMaintainsBuy$88 → $105
12 Aug 2026OppenheimerMaintainsOutperform$97 → $100
12 Aug 2026OppenheimerMaintainsOutperform—
31 July 2026MizuhoMaintainsOutperform—
31 July 2026MizuhoMaintainsOutperform$100 → $98
21 July 2026GuggenheimMaintainsBuy$90 → $89
21 July 2026GuggenheimMaintainsBuy—
9 July 2026HC Wainwright & Co.ReiteratesBuy—
9 July 2026HC Wainwright & Co.ReiteratesBuy$88
4 May 2026HC Wainwright & Co.ReiteratesBuy—
25 Feb 2026GuggenheimMaintainsBuy—
25 Feb 2026OppenheimerMaintainsOutperform—
9 Dec 2025BarclaysInitiatesOverweight—
20 Nov 2025MizuhoInitiatesOutperform—
5 Nov 2025GuggenheimMaintainsBuy—
20 Oct 2025HC Wainwright & Co.MaintainsBuy—
27 May 2025HC Wainwright & Co.AssumesBuy$72
5 May 2025Goldman SachsMaintainsNeutral—
2 May 2025GuggenheimMaintainsBuy—
6 Mar 2025JefferiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TARS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TARS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, Tarsus Pharmaceuticals, Inc. returned +62.0% against +17.0% for the S&P 500, dividends included.

TARS vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180Oct 25Jan 26Apr 26Jul 26TARSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TARS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Tarsus Pharmaceuticals, Inc. (TARS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−50.3×

Cheaper than 98% of US stocks

Price / sales
6.2×

Cheaper than 21% of US stocks

Price / book
10.0×

Cheaper than 10% of US stocks

EV / EBITDA
−67.5×

Cheaper than 95% of US stocks

Growth & margins
Revenue growth (YoY)
69.4%

Higher than 90% of US stocks

Earnings growth (YoY)
69.4%

Higher than 79% of US stocks

Gross margin
93.0%

Higher than 97% of US stocks

Operating margin
−11.4%

Higher than 24% of US stocks

Net margin
−7.7%

Higher than 21% of US stocks

Returns & dividend
Return on equity
−13.7%

Higher than 34% of US stocks

Return on assets
−5.5%

Higher than 31% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Tarsus Pharmaceuticals, Inc. (TARS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Tarsus Pharmaceuticals, Inc. has a market value of $3.7B and an enterprise value of $3.1B.

  • Revenue in the twelve months to 30 June 2026: $606.3M. The latest quarter grew 69.4% year on year.

  • Net income over the same four quarters: −$46.5M, a −7.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.09.

  • Free cash flow in the twelve months to 30 June 2026: $56.0M.

  • Shares outstanding: 43.3M.

  • Trailing P/E: −50.3×; forward P/E: 33.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Tarsus Pharmaceuticals, Inc. employs 370 people — $1.6M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Sept 2026

Data provided by Twelve Data

Peers

TARS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TARSTarsus Pharmaceuticals, Inc.$3.7B
83
DYNDyne Therapeutics, Inc.$3.4B
23
DNLIDenali Therapeutics, Inc.$3.3B
58
IDYAIDEAYA Biosciences, Inc.$3.6B
80
ABCLAbCellera Biologics, Inc.$3.6B
71
VKTXViking Therapeutics, Inc.$3.6B
28
QUREUniQure NV$3.1B
60

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Tarsus Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TARS news & analysis

Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care

GlobeNewsWire · 4 Sept 2026positive

Tarsus Pharmaceuticals announced the completion of its previously announced acquisition of Alkeus Pharmaceuticals, a privately held retinal disease-focused biotechnology company. The deal adds gildeuretinol (ALK-001), a Phase 3 oral investigational medicine targeting the underlying biology of Stargardt's disease, a potentially blinding condition with no FDA-approved therapy.

Why it matters — For Tarsus watchers, the completed acquisition adds a differentiated Phase 3 eye-care asset and strengthens Tarsus' pipeline and leadership in eye care.

Alkeus Announces Publication in JAMA Ophthalmology of Efficacy and Safety Results from the TEASE-1 Study of Gildeuretinol in Stargardt Disease

GlobeNewsWire · 3 Sept 2026neutral

Alkeus announced publication in JAMA Ophthalmology of efficacy and safety results from the TEASE-1 study of gildeuretinol in Stargardt disease. Daily oral treatment met its primary endpoint with a statistically significant reduction in the growth rate of retinal atrophic lesions versus the untreated group, and was well tolerated with no reported dark adaptation delays or night blindness.

Why it matters — TARS watchers would care because this is a peer-reviewed efficacy and safety result in a retinal disease space relevant to Tarsus's ophthalmology focus, providing competitive context for its own pipeline.

Tarsus to Participate in Upcoming Investor Conferences

GlobeNewsWire · 1 Sept 2026neutral

Tarsus Pharmaceuticals announced that its management plans to attend upcoming investor conferences, including the Wells Fargo 21st Annual Healthcare Conference on September 8th. No additional details were provided.

Why it matters — TARS watchers would care because management's participation signals ongoing investor engagement and visibility at key industry events.

Alkeus Pharmaceuticals Announces Japan Ministry of Health, Labour and Welfare (MHLW) Has Granted Orphan Drug Designation to Gildeuretinol for Stargardt Disease

GlobeNewsWire · 24 Aug 2026neutral

Alkeus Pharmaceuticals announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug Designation to its oral gildeuretinol for the treatment of Stargardt disease. The designation was granted to the biopharmaceutical company focused on preserving sight for people with retinal diseases.

Why it matters — The item signals regulatory progress for a treatment in the retinal-disease space, an area relevant to watchers of ophthalmic stocks such as Tarsus, though the release does not mention Tarsus directly.

Tarsus Pharmaceuticals Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026neutral

Tarsus Pharmaceuticals reported second-quarter growth in sales of its Demodex blepharitis treatment XDEMVY. The company also announced a pending acquisition of Alkeus Pharmaceuticals, which would add the late-stage investigational Stargardt disease therapy gildeuretinol (ALK-001) to its pipeline.

Why it matters — A TARS watcher would care because the report confirms continued commercial growth of XDEMVY and signals a potential pipeline expansion into the Stargardt disease treatment space through the Alkeus acquisition.

FAQ

Frequently asked questions about TARS stock

What is the TARS stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Tarsus Pharmaceuticals, Inc. have a median 12-month price target of $100, with estimates ranging from $84 to $105. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TARS stock a buy right now?

Of the 8 analysts covering Tarsus Pharmaceuticals, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tarsus Pharmaceuticals, Inc. 83 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TARS?

As at 14 Sept 2026, Tarsus Pharmaceuticals, Inc. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).

Will TARS stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +24.5% from the last close, and Ticker Nerd's factor model ranks Tarsus Pharmaceuticals, Inc. 83 out of 100 as at 14 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TARS stock forecast for 2030?

No analyst covering Tarsus Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TARS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $84 to $105 over the next 12 months.

How has TARS stock performed over the past year?

Tarsus Pharmaceuticals, Inc. returned +62.0% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tarsus Pharmaceuticals, Inc. do?

Tarsus Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on eye care.

What is the latest news on TARS?

The most recent item we track (GlobeNewsWire, 4 Sept 2026): "Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care". Tarsus Pharmaceuticals announced the completion of its previously announced acquisition of Alkeus Pharmaceuticals, a privately held retinal disease-focused biotechnology company. The deal adds gildeuretinol (ALK-001), a Phase 3 oral investigational medicine targeting the underlying biology of Stargardt's disease, a potentially blinding condition with no FDA-approved therapy.

Company

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on eye care. The company develops and commercializes therapies for diseases of the ocular surface, with its lead product addressing demodex blepharitis, a common eyelid condition caused by Demodex mites. Tarsus Pharmaceuticals also advances additional ophthalmology assets and supports a broader eye-care franchise aimed at treating unmet needs in outpatient and specialist settings. Its business combines drug development, regulatory execution, and commercial distribution, making it an important participant in the ophthalmology and specialty pharmaceuticals market. Headquartered in Irvine, California, Tarsus Pharmaceuticals Inc. concentrates on transforming proven science into targeted treatments for patients and eye-care providers.

CEO Dr. Bobak R. Azamian M.D. · 370 employees · United States · https://tarsusrx.com